原发性肝癌患者接受TACE术时行右美托咪定联合吗啡麻醉临床应用价值分析

doi:10.3969/j.issn.1672-5069.2021.02.028

Abstract

Abstract: Objective The aim of this study was to investigate the analgesia of dexmedetomidine and morphine in patients with primary liver cancer (PLC) undergoing transcatheter hepatic arterial chemoembolization (TACE) .Methods A total of 125 patients with PLC were enrolled in our hospital between July 2018 and July 2020, and all underwent TACE. During the procedure, the patients with PLC were divided into group A (n=64) receiving dexmedetomidine and morphine for analgesia, and group B (n=61) receiving morphine for analgesia. The treatment was in an intravenous patient-controlled way. The visual analogue scale (VAS) and modified observers assessment of alertness/sedation scale (OAA/S) were applied for assessment of analgesia immediately after embolization (T0), completion of surgery (T1), 12 h (T2) after surgery, and 24 h (T3) after surgery. The mean arterial blood pressure (MAP), systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were monitored.Results At T0, T1, T2 and T3, the VAS scores in group A were (2.4±1.1), (2.0±0.9), (1.7±0.5) and (1.2±0.3), significantly lower than [(2.9±1.5), (2.5±1.3), (2.0±0.9) and (1.6±0.5), respectively, P < 0.05] in group B; at T0, T1, T2 and T3, the OAA/S scores in group A were (4.6±0.3), (4.5±0.3), (4.7±0.2) and (4.6±0.2), not significantly different compared to [ (4.5±0.3), (4.5±0.2), (4.6±0.4) and (4.6±0.2), respectively, P > 0.05] in group B; there were no significant differences as respect to MAP, SBP, DBP and HR in the two groups at any times (P > 0.05); the overall incidence of adverse reactions in group A was significantly lower than that in group B (12.5% vs. 27.9%, P < 0.05); the effective rate and disease control rate in group A after treatment were 67.2% and 73.4%, not statistically significantly different compared with 68.9% and 75.4%, respectively, in group B (P>0.05).Conclusion The application of dexmedetomidine and morphine combination for analgesia in an intravenous patient-controlled way in patients with PLC underwent TACE is effective and simple, which might relieve pain with less incidence of adverse reactions.

Key words: Hepatoma, Transhepatic arterial chemoembolization, Dexmedetomidine, Morphine, Analgesia

Zhao Chuang, Liang Chao, Dong Baojian, et al. Analgesia of dexmedetomidine and morphine in patients with primary liver cancer undergoing transcatheter hepatic arterial chemoembolization[J]. Journal of Practical Hepatology, 2021, 24(2): 260-263.

References

[1] Malki A, El-Sharkawy A, Mohamed M, et al. Antitumor activities of the novel isosteviol derivative 10c against liver cancer. Anticancer Res, 2017, 37(4):1591-1601.
[2] Nakashima T, Okuda K, Kojiro M, et al. Primary liver cancercoincident with schistosomiasis japonica. a study of 24 necropsies. Cancer, 1975, 36(4):1483-1489.
[3] Benzakoun J, Ronot M, Lagadec M, et al. Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int, 2017, 37(4):583-591.
[4] Jeleazcov C, Ihmsen H, Saari TI, et al. Patient-controlled analgesia with target-controlled infusion of hydromorphone in postoperative pain therapy. Anesthesiology, 2015, 124(1):56-68.
[5] 中国抗癌协会肝癌专业委员会(CSLC), 中国抗癌协会临床肿瘤学协作专业委员会(CSCO), 中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治的专家共识. 实用肝脏病杂志, 2009, 12(5):321-328.
[6] 閤谦, 吴骋, 童林军, 等. RECIST1.1、PERCIST1.0、WHO及EORTC用于评价结直肠癌肝脏转移化疗后疗效的比较. 中华核医学与分子影像杂志, 2017, 37(9):559-563.
[7] Rodríguez-Sánchez J, Torrijos E G, Escobedo R M, et al. Su1855 vas-eoe score: a new symptoms-assessment tool for eosinophilic esophagitis. Gastroenterology, 2013, 144(5):492-493.
[8] Robinson BRH, Berube M, Barr J, et al. Psychometric analysis of subjective sedation scales in critically ill adults. Crit Care Med, 2013, 41(9):16-29.
[9] Faigel DO, Lake DF, Landreth TL, et al. EUS-guided portal injection chemotherapy for treatment of hepatic metastases: feasibility in the acute porcine model. Gastrointest Endosc, 2016, 83(2):444-446.
[10] Napoletano C, Taurino F, Biffoni M, et al. Rfa strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol, 2008, 32(2):481-490.
[11] Aliberti C, Carandina R, Sarti D, et al. Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy. Anticancer Res, 2016, 36(7):3515-3521.
[12] Lam C, Yuen W, Fan S. Hepatic cryosurgery for recurrent hepatocellular carcinoma after hepatectomy: a preliminary report. J Surg Oncol, 1998, 68(2):104-106.
[13] Zhang R, Tian X, Qin L, et al. Factors predicting abnormal liver function tests induced by graves’disease alone: a retrospective cohort study. Medicine, 2015, 94(19):e839.
[14] Kazutaka K, Naoki H, Akira Y, et al. Successful treatment of large-size advanced hepatocellular carcinoma by transarterial chemoembolization followed by the combination therapy of percutaneous ethanol-lipiodol injection and radiofrequency ablation. Oncol Rep, 2006, 16(5):1067-1070.
[15] Qi X, Chen D, Li G, et al. Comparison of intrathecal dexmedetomidine with morphine as adjuvants in cesarean sections. Biol Pharm Bull, 2016, 39(9):1455-1460.
[16] Ge DJ, Qi B, Tang G, et al. Intraoperative dexmedetomidine promotes postoperative analgesia in patients after abdominal colectomy: a consort-prospective, randomized,controlled clinical trial. Medicine, 2015, 94(43):e1514.
[17] Abdallah FW , Tim D, Vincent WSC, t al. IV and perineural dexmedetomidine similarly prolong the duration of analgesia after interscalene brachial plexus block: a randomized, three-arm, triple-masked, placebo-controlled trial. Anesthesiology, 2016, 124(3):683-695.
[18] Garg N, Panda NB, Gandhi KA, et al. Comparison of small dose ketamine and dexmedetomidine infusion for postoperative analgesia in spine surgery-a prospective randomized double-blind placebo controlled study. J Neurosurg Anesthesiol, 2016, 28(1):27-31.
[19] 谢广伦, 张卫, 李志刚, 等. 小剂量右美托咪定混合吗啡PCIA对阿片类药物耐受-口服困难患者癌痛的疗效. 中华麻醉学杂志, 2018, 38(8):937-941.
[20] 王宏伟, 李兰兰, 李治松, 等. 盐酸氢吗啡酮联合右美托咪定对经皮肝动脉化疗栓塞术治疗患者的静脉自控镇痛效果. 中华肿瘤杂志, 2018, 40(8):626-630.

Analgesia of dexmedetomidine and morphine in patients with primary liver cancer undergoing transcatheter hepatic arterial chemoembolization

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Luo Weixin, Liu Chaoqun, Xu Leibo, et al. Effects of exosomes derived from rat liver cancer cells with different lung metastasis potentials on the transcriptome of macrophages [J]. Journal of Practical Hepatology, 2021, 24(3): 312-318.
[2]	Chen Shaohua, Wu Zhe, Wei Zhihong, et al. Serum oncogene and tumor suppressor gene levels in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(2): 244-247.
[3]	Mo Juan, Yan Wen, Xu Shaoqiang. Short-term and long-termsurvivals of patients with huge primary liver cancer after associated liver partition and portal vein ligation for staged hepatectomy [J]. Journal of Practical Hepatology, 2021, 24(2): 252-255.
[4]	Zhu Yaping, Wei Jinju, Wang Yanxin, et al. Continuous pumping propofol in anaesthetizing patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(2): 292-293.
[5]	Li Xiaoyan, Hu Heping. Internal management of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 1-3.
[6]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[7]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[8]	Zhang Xue, Xu Ying, An Wenhui,et al. Value of five scoring systems in predicting liver dysfunction after transcatheter arterial chemoembolization in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 111-114.
[9]	Qiao Min, Zhao Yijian,Z hang Jianqiao,et al. Efficacy of TACE and radiofrequency ablation combination in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 119-122.
[10]	Li Yamin, Wang Ruiting, Wang Yingying. Short-term efficacy of radiofrequency ablation with cold circulation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 123-126.
[11]	Xie huanyu, Gong Jinwei, Zhao MingXing, et al. Inhibitoryeffects of Fe₃O₄ nanometer magnetic carrier-induced hyperthermia under extremely low frequency electromagnetic fields on implanted tumors in nude mice [J]. Journal of Practical Hepatology, 2020, 23(6): 777-780.
[12]	Hu Xia, Zhai Xiaofeng, Gu Wei, et al. Cyberknife stereotactic radiotherapy and transcatheter arterial chemoembolization as an option of treatment for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2020, 23(6): 881-884.
[13]	Han Pengwei, Wang Huming, Zhao Tianyong. Clinical feature and prognostic factors of primary liver cancer patients with serum AFP negative after TACE [J]. Journal of Practical Hepatology, 2020, 23(5): 715-718.
[14]	Zhou Binbin,Sun Yaochen,Huang Haifan, et al.. Evaluation of functional magnetic resonance imaging in patients with hepatocellular carcinoma after TACE [J]. Journal of Practical Hepatology, 2020, 23(5): 723-726.
[15]	Liu Xu, Hu Yuchang, Cheng Lu, et al.. Clinicopathological manifestation of primary liver adenosquamous carcinoma: An analysis of six cases [J]. Journal of Practical Hepatology, 2020, 23(5): 727-730.